Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
- PMID: 11877296
- DOI: 10.1182/blood.v99.6.2185
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
Abstract
Multiple myeloma (MM) is a plasma-cell malignancy characterized by marked epidemiological, biological, and clinical heterogeneity. The goal of this study was to find a genetic basis for this heterogeneity. Using fluorescence in situ hybridization, we analyzed a prospective cohort of 901 patients with various plasma-cell disorders--monoclonal gammopathies of undetermined significance, smoldering MM, MM, and primary plasma-cell leukemia--for genetic abnormalities involving the 13q14 and 14q32 chromosomal regions; the patients were consecutively enrolled in the Intergroupe Francophone du Myélome clinical trials, We performed statistical analyses comparing these chromosomal abnormalities in terms of immunological (ie, immunoglobulin types and light-chain subtypes) and clinical status and, to some extent, prognostic features. It was found that 14q32 translocations and del(13) are the most frequent chromosomal abnormalities, observed in 75% and 45% of the patients, respectively, and are not randomly distributed, but interconnected. Second, correlations between them allowed us to define 4 major genetic categories of patients: (1) patients lacking any 14q32 abnormality (25%) and generally also lacking del(13); (2) patients presenting either t(4;14) or t(14;16), almost always associated with a del(13) (15% of patients); (3) patients with other 14q32 abnormalities and presenting del(13) (25%); and (4) patients with other 14q32 abnormalities but not presenting del(13) (35%). Third, we show that this genetic stratification is highly correlated with immunological status and clinical presentation and with some major prognostic factors. For the first time, this study gives genetic support to the heterogeneity observed in patients with MM and demonstrates that the 14q32 and 13q chromosomal abnormalities are not randomly distributed. The strong correlations we found might be the basis for a novel genetic classification of MM, as has been previously demonstrated for leukemias and lymphomas. Furthermore, our study supports different models for MM oncogenesis.
Similar articles
-
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.Blood. 1999 Oct 15;94(8):2583-9. Blood. 1999. PMID: 10515861
-
The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.Blood. 1997 Jul 15;90(2):526-34. Blood. 1997. PMID: 9226151
-
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.Exp Oncol. 2007 Jun;29(2):116-20. Exp Oncol. 2007. PMID: 17704743
-
[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].Rev Med Interne. 2007 Oct;28(10):677-81. doi: 10.1016/j.revmed.2007.04.013. Epub 2007 May 25. Rev Med Interne. 2007. PMID: 17559979 Review. French.
-
Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia.Leuk Lymphoma. 1996 Mar;21(1-2):25-30. doi: 10.3109/10428199609067575. Leuk Lymphoma. 1996. PMID: 8907265 Review.
Cited by
-
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.Blood Cancer J. 2012 Sep 7;2(9):e89. doi: 10.1038/bcj.2012.37. Blood Cancer J. 2012. PMID: 22961061 Free PMC article.
-
Minor clone provides a reservoir for relapse in multiple myeloma.Leukemia. 2013 Feb;27(2):473-81. doi: 10.1038/leu.2012.226. Epub 2012 Aug 9. Leukemia. 2013. PMID: 22874878 Free PMC article.
-
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
-
Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.Haematologica. 2013 Feb;98(2):279-87. doi: 10.3324/haematol.2011.060632. Epub 2012 Aug 28. Haematologica. 2013. PMID: 22929983 Free PMC article.
-
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.Am J Pathol. 2003 May;162(5):1449-61. doi: 10.1016/S0002-9440(10)64278-2. Am J Pathol. 2003. PMID: 12707028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials